ANDA 204115, held by Novel Laboratories. Methylphenidate Hydrochloride.
As of Nov 21, 2026, ANDA 204115 (Methylphenidate Hydrochloride), held by Novel Laboratories, was first approved by FDA on Feb 25, 2015, with 6 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Attention Deficit Disorders, Narcolepsy Attention Deficit Disorders (previously known as Minimal Brain Dysfunction in Children). Other terms being used to describe the behavioral syndrome below include: Hyperkinetic Child Syndrome, Minimal Brain Damage, Minimal Cerebral Dysfunction, Minor Cerebral Dysfunction.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 25, 2015 | Original application | Approved |
| Methylphenidate Hydrochloride2.5MG · tablet, chewable;oral | Methylphenidate Hydrochloride | Discontinued |
| Methylphenidate Hydrochloride5MG · tablet, chewable;oral | Methylphenidate Hydrochloride | Discontinued |
| Methylphenidate Hydrochloride10MG · tablet, chewable;oral | Methylphenidate Hydrochloride | Discontinued |
| Mar 18, 2025 | Supplement 9Labeling · Standard review | Approved | None posted |
| Mar 28, 2024 | Supplement 8Labeling · Standard review | Approved | None posted |
| Oct 20, 2023 | Supplement 7Labeling · Standard review | Approved | None posted |
| Jun 25, 2021 | Supplement 5Labeling · Standard review | Approved | None posted |
| Jan 4, 2017 | Supplement 3Labeling · Standard review | Approved | None posted |
| Dec 27, 2016 | Supplement 2Labeling · Standard review | Approved | None posted |
| Feb 25, 2015 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters